USING IMMUNOMODULATING DRUG GALAVIT IN TREATMENT OF INFLUENZA
https://doi.org/10.17650/1818-8338-2012-6-2-76-80
Abstract
Aim – to evaluate the effectiveness of immunomodulating drug Galavit in patients with uncomplicated influenza. Materials and methods. Non-randomized single-center comparative study was performed. Patients with influenza (male, average age – 25,1 ± 1,3 years, n = 45) were divided into 2 groups. Study group (n = 20) from the time of admission received the drug Galavit in addition to symptomatic and detoxification therapy. Patients in the control group (n = 25) received only symptomatic and detoxication therapy. The criterion of effectiveness of the preparation was positive dynamics of clinical symptoms and the results of clinical blood. Results. For the 2nd day of the disease 15 % of patients of the group returned to normal body temperature (in the control group, none of the patients had normal body temperature to the 2nd day of illness). By the 5th day of observation, 95 % of the study group patients showed normalization of body temperature (in the control group – 84 % of patients). Catarrhal symptoms resolved faster in patients of the main group than in patients of control group. Patients treated with Galavit observed normal levels of white blood cells and ESR by the moment of hospital discharge, in the control group leukocytosis and increased ESR remained. Conclusion. Galavit drug reduces the duration of catarrhal and intoxication syndrome in patients with influenza, effect positively on hematological parameters: helps reduce the number of white blood cells, stab shift, normalization of ESR.
About the Authors
T. V. Sologub
Research Institute of Influenza, Russian Ministry of Health;
Mechnikov Northwestern State Medical University
Russian Federation
Russian Federation
O. Y. Osinovets
Mechnikov Northwestern State Medical University
Russian Federation
Russian Federation
References
1. Cheng V.C., To K.K., Tse H. et al. Two years after pandemic influenza A/2009/ H1N1: what have we learned? Clin Microbiol Rev 2012;25(2):223–63.
2. Carrillo-Santisteve P., Ciancio B.C., Nicoll A., Lopalco P.L.The importance
3. of influenza prevention for public health. Hum Vaccin Immunother. 2012;8(1):89–95.
4. Синопальников А.И., Белоцерковская Ю.Г. Диагностика, профилактика и лечение гриппа. Клиницист 2006;(1):23–33.
5. Hsu J., Santesso N., Mustafa R. et al. Antivirals for treatment of influenza:
6. a systematic review and meta-analysis of observational studies. Ann Intern Med. 2012;156(7):512–24.
7. Лазебник Л.Б., Гориловский Л.М., Климанова Е.А., Конев Ю.В. Экономические преимущества многоцелевой монотерапии доксазозином пожилых больных с сочетанной патологией. Клинич. геронтол. 2003;9(11):43–7.
8. Silin D.S., Lyubomska O.V., Ershov F.I. et al. Synthetic and natural immunomodulators acting as interferon inducers. Curr Pharm Des. 2009;15(11):1238–47.
9. Барышникова М.А., Ахматова Н.К., Карамзин A.M. Иммуномодулирующая активность сублингвальной формы галавита. Рос. биотер. журн. 2007;6(2):55–8.
10. Романцов М.Г., Сологуб Т.В., Петров А.Ю., Коваленко А.Л. Циклоферон в экстренной профилактике респираторных вирусных инфекций и гриппа. Клин. мед. 2011;89(1):51–4.
11. Боковикова Т.Н., Багирова В.Л., Черникова Е.П. и др. Новый препарат галавит: методы анализа и стандартизации. Фарматека 1999;(2):53–5.
12. Латышева Т.В., Сетдикова Н.Х., Манько К.С. Вторичные иммунодефициты. Возможности использо вания отечественного иммуномодулятора галавит. Цитокины и воспаление 2005; 4(3):95–9.
13. Латышева Т.В., Щербакова О.В. Клинические аспекты использования отечественного иммуномодулятора Галавита. Фарматека 2004;(7):51–4.
14. Куликова Т.Ю., Гурина О.И. Галавит в комплексной терапии больных с астеническими расстройствами. Рос. психиатр. журн 2006;(6):75–81.
Review
For citations:
Sologub T.V., Osinovets O.Y. USING IMMUNOMODULATING DRUG GALAVIT IN TREATMENT OF INFLUENZA. The Clinician. 2012;6(2):76-80. (In Russ.) https://doi.org/10.17650/1818-8338-2012-6-2-76-80
Views:
2415
Email this article 